Literature DB >> 28687688

Contribution of arterial spin-labelling MRI in a case with immune reconstitution inflammatory syndrome.

Noriaki Wada1, Tomoyuki Noguchi1, Takahiro Aoki2, Tsuyoshi Tajima1.   

Abstract

Central nervous system immune reconstitution inflammatory syndrome (CNS-IRIS), which occurs most often in HIV-infected patients, is an exacerbation of inflammatory reactions related to opportunistic infections as well as primary CNS malignancies both of which mostly occur in HIV-infected patients. However, differential diagnoses are challenging both clinically and radiologically. We describe a patient with CNS-IRIS due to toxoplasmosis whose 11C-methionine uptake suggested lymphoma but whose arterial spin-labelling MRI led to the correct diagnosis. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  Neuroimaging; Radiology

Mesh:

Year:  2017        PMID: 28687688      PMCID: PMC5534855          DOI: 10.1136/bcr-2017-219860

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  9 in total

Review 1.  Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis.

Authors:  Monika Müller; Simon Wandel; Robert Colebunders; Suzanna Attia; Hansjakob Furrer; Matthias Egger
Journal:  Lancet Infect Dis       Date:  2010-04       Impact factor: 25.071

2.  Lymphoma immune reconstitution inflammatory syndrome in the center for AIDS research network of integrated clinical systems cohort.

Authors:  Satish Gopal; Monita R Patel; Chad J Achenbach; Elizabeth L Yanik; Stephen R Cole; Sonia Napravnik; Greer A Burkholder; W Christopher Mathews; Benigno Rodriguez; Steven G Deeks; Kenneth H Mayer; Richard D Moore; Mari M Kitahata; Kristy L Richards; Joseph J Eron
Journal:  Clin Infect Dis       Date:  2014-04-21       Impact factor: 9.079

3.  Clinical presentation and diagnosis of toxoplasmic encephalitis in Japan.

Authors:  Naoya Sakamoto; Takuya Maeda; Kei Mikita; Yasuyuki Kato; Naoki Yanagisawa; Akihiko Suganuma; Akifumi Imamura; Fukumi Nakamura-Uchiyama; Yasushi Miyahira; Akihiko Kawana; Kenji Ohnishi; Atsushi Ajisawa
Journal:  Parasitol Int       Date:  2014-06-11       Impact factor: 2.230

4.  Use of PET in the diagnosis of primary CNS lymphoma in patients with atypical MR findings.

Authors:  Nobuyuki Kawai; Shuichi Okubo; Keisuke Miyake; Yukito Maeda; Yuka Yamamoto; Yoshihiro Nishiyama; Takashi Tamiya
Journal:  Ann Nucl Med       Date:  2010-04-09       Impact factor: 2.668

5.  Primary central nervous system lymphoma in acquired immune deficiency syndrome mimicking toxoplasmosis.

Authors:  Satoshi Utsuki; Hidehiro Oka; Katsutoshi Abe; Shigeyuki Osawa; Tomoya Yamazaki; Yoshie Yasui; Kiyotaka Fujii
Journal:  Brain Tumor Pathol       Date:  2011-01-06       Impact factor: 3.298

6.  Differentiating primary CNS lymphoma from glioblastoma multiforme: assessment using arterial spin labeling, diffusion-weighted imaging, and ¹⁸F-fluorodeoxyglucose positron emission tomography.

Authors:  Koji Yamashita; Takashi Yoshiura; Akio Hiwatashi; Osamu Togao; Koji Yoshimoto; Satoshi O Suzuki; Koichiro Abe; Kazufumi Kikuchi; Yasuhiro Maruoka; Masahiro Mizoguchi; Toru Iwaki; Hiroshi Honda
Journal:  Neuroradiology       Date:  2012-09-09       Impact factor: 2.804

7.  Increased glial metabolites predict increased working memory network activation in HIV brain injury.

Authors:  T Ernst; L Chang; S Arnold
Journal:  Neuroimage       Date:  2003-08       Impact factor: 6.556

8.  Methionine PET for follow-up of radiation therapy of primary lymphoma of the brain.

Authors:  T Ogawa; I Kanno; J Hatazawa; A Inugami; H Fujita; E Shimosegawa; M Murakami; T Okudera; K Uemura; N Yasui
Journal:  Radiographics       Date:  1994-01       Impact factor: 5.333

9.  Carbon-11-methionine and fluorine-18-FDG PET study in brain hematoma.

Authors:  S Dethy; S Goldman; S Blecic; A Luxen; M Levivier; J Hildebrand
Journal:  J Nucl Med       Date:  1994-07       Impact factor: 10.057

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.